Premium
Manchester iStent study: early results from a prospective UK case series
Author(s) -
Patel Ilesh,
Klerk Timothy A,
Au Leon
Publication year - 2013
Publication title -
clinical and experimental ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.3
H-Index - 74
eISSN - 1442-9071
pISSN - 1442-6404
DOI - 10.1111/ceo.12098
Subject(s) - medicine , intraocular pressure , glaucoma , ophthalmology , visual acuity , open angle glaucoma , prospective cohort study , adverse effect , glaucoma medication , surgery
Background To evaluate the 6‐month efficacy and safety of the iStent microtrabecular bypass stent in patients with open‐angle glaucoma. Design A prospective, uncontrolled, interventional case series. Participants Forty‐four eyes with open‐angle glaucoma were reported. Methods All subjects underwent ab interno implantation of a single iStent together with ( n = 40) or without ( n = 4) cataract surgery. Main Outcome Measures Patients were assessed at postoperative week 1, months 1 and 3, and quarterly, thereafter. Data collected included visual acuity, intraocular pressure measurement using G oldmann tonometry, number of glaucoma medications, and number and type of complications. Results The mean age of the sample was 76.8 years. The mean duration since glaucoma diagnosis was 5.3 years (standard deviation 2.9 years). The mean visual acuity was 0.53 logMAR at baseline that improved to 0.23 at 6 months postoperatively. The mean baseline intraocular pressure was 21.1 mm H g, and this decreased significantly to 16.7 mm H g at 6 months ( P < 0.01). The mean number of drops prescribed preoperatively was 2.3, which decreased to 0.6 at 6 months ( P < 0.01). Sixty‐six per cent of patients were drop‐free at 6 months. One patient developed an hyphaema following surgery; no other adverse events were recorded. Conclusions The iStent proved to be a safe and effective treatment for patients with open‐angle glaucoma over our 6‐month follow up period. Insertion resulted in a significant decrease in intraocular pressure as well as the number of topical antiglaucoma medications required for adequate intraocular pressure control.